Seroatlas · Human Serome Atlas

TRPC6

Short transient receptor potential channel 6

Also known as: FSGS2, TRP6, TRPC6_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9Y210
Gene
TRPC6
Ensembl
ENSG00000137672
Chromosome
11
Canonical length
931 aa
Protein class
Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene forms a receptor-activated calcium channel in the cell membrane. The channel is activated by diacylglycerol and is thought to be under the control of a phosphatidylinositol second messenger system. Activation of this channel occurs independently of protein kinase C and is not triggered by low levels of intracellular calcium. Defects in this gene are a cause of focal segmental glomerulosclerosis 2 (FSGS2). [provided by RefSeq, Mar 2009]

Canonical amino-acid sequenceUniProt

931 residues, UniProt reviewed canonical sequence.

>Q9Y210|TRPC6
     1  MSQSPAFGPR RGSSPRGAAG AAARRNESQD YLLMDSELGE DGCPQAPLPC YGYYPCFRGS
    61  DNRLAHRRQT VLREKGRRLA NRGPAYMFSD RSTSLSIEEE RFLDAAEYGN IPVVRKMLEE
   121  CHSLNVNCVD YMGQNALQLA VANEHLEITE LLLKKENLSR VGDALLLAIS KGYVRIVEAI
   181  LSHPAFAEGK RLATSPSQSE LQQDDFYAYD EDGTRFSHDV TPIILAAHCQ EYEIVHTLLR
   241  KGARIERPHD YFCKCNDCNQ KQKHDSFSHS RSRINAYKGL ASPAYLSLSS EDPVMTALEL
   301  SNELAVLANI EKEFKNDYKK LSMQCKDFVV GLLDLCRNTE EVEAILNGDV ETLQSGDHGR
   361  PNLSRLKLAI KYEVKKFVAH PNCQQQLLSI WYENLSGLRQ QTMAVKFLVV LAVAIGLPFL
   421  ALIYWFAPCS KMGKIMRGPF MKFVAHAASF TIFLGLLVMN AADRFEGTKL LPNETSTDNA
   481  KQLFRMKTSC FSWMEMLIIS WVIGMIWAEC KEIWTQGPKE YLFELWNMLD FGMLAIFAAS
   541  FIARFMAFWH ASKAQSIIDA NDTLKDLTKV TLGDNVKYYN LARIKWDPSD PQIISEGLYA
   601  IAVVLSFSRI AYILPANESF GPLQISLGRT VKDIFKFMVI FIMVFVAFMI GMFNLYSYYI
   661  GAKQNEAFTT VEESFKTLFW AIFGLSEVKS VVINYNHKFI ENIGYVLYGV YNVTMVIVLL
   721  NMLIAMINSS FQEIEDDADV EWKFARAKLW FSYFEEGRTL PVPFNLVPSP KSLFYLLLKL
   781  KKWISELFQG HKKGFQEDAE MNKINEEKKL GILGSHEDLS KLSLDKKQVG HNKQPSIRSS
   841  EDFHLNSFNN PPRQYQKIMK RLIKRYVLQA QIDKESDEVN EGELKEIKQD ISSLRYELLE
   901  EKSQNTEDLA ELIRELGEKL SMEPNQEETN R

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRPC6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
6
Mean surface accessibility (rSASA)
0.38
Highest tissue expression
20 nTPM

Expression across tissuesHPA

Tissue

  • placenta: 20 nTPM
  • lung: 13 nTPM
  • thyroid gland: 8.8 nTPM
  • choroid plexus: 5.5 nTPM
  • esophagus: 5.3 nTPM
  • fallopian tube: 5.1 nTPM

Single-cell type

  • ependymal cells: 247 nCPM
  • podocytes: 241 nCPM
  • pericytes: 197 nCPM
  • megakaryocyte progenitors: 130 nCPM
  • choroid plexus epithelial cells: 107 nCPM
  • vascular smooth muscle cells: 93 nCPM

Immune cell

  • eosinophil: 2.3 nTPM
  • plasmacytoid DC: 0.4 nTPM
  • myeloid DC: 0.3 nTPM
  • non-classical monocyte: 0.2 nTPM
  • total PBMC: 0.1 nTPM
  • basophil: 0 nTPM

Brain region

  • choroid plexus: 12 nTPM
  • midbrain: 7.3 nTPM
  • hypothalamus: 4.2 nTPM
  • medulla oblongata: 4 nTPM
  • spinal cord: 3.4 nTPM
  • cerebral cortex: 3.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRPC6.

Disease | AllUniProt

Conditions TRPC6 is implicated in, by any mechanism.

  • Focal segmental glomerulosclerosis 2 (FSGS2) MIM:603965

Disease | GeneticClinVar

36 pathogenic / likely-pathogenic of 576 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.65
gnomAD pLI
0
gnomAD missense Z
2.12
DepMap mean gene effect
-0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRPC6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRPC6 as an antibody target. Whether an autoantibody or antibody against TRPC6 could matter depends on whether native TRPC6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRPC6 is annotated at the cell surface, where native TRPC6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TRPC6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TRPC6. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...